Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Despite the emerging success of immunotherapy in non-small-cell lung cancer (NSCLC), it remains clinically important to better identify patients who are likely to respond to treatment, especially considering the existence of immune-related adverse events (irAEs). In recent years, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ben, Chau, Justin, Dai, Qun, Zhong, Cuncong, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656313/
https://www.ncbi.nlm.nih.gov/pubmed/36358819
http://dx.doi.org/10.3390/cancers14215401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656313/
https://www.ncbi.nlm.nih.gov/pubmed/36358819
http://dx.doi.org/10.3390/cancers14215401

Ejemplares similares